Skip to main content
Equibles
BIOA logo

BIOA · BioAge Labs, Inc.

Track BIOA — free

Use BIOA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BIOA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.49 -0.16 (-1.85%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$389.66M
Shares
45.90M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$8.49 Open$8.71 Day$8.28–8.89 52W close$4.80–25.10 Avg vol 30d1.1M Short int2.7M · 5.9% float · 4.7d Short vol38% Last earningsAug 5, 2026 DataSep 2024–Sep 2026 Filing10-Q · Aug 5

Up next

Latest filing: 10-Q
filed Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$10.36M
Trailing 12 months
Net income (TTM)
−$94.46M
Trailing 12 months
Revenue growth YoY
+1.6%
Year over year
Operating margin
-1,026.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-22.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+25.1%
Year over year · more shares
Price change (1Y)
+72.9%
Trailing year
Short interest
5.9%
Latest settlement · 4.7 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −50%
below
Price vs 50-day avg −44%
below
RSI (14) 29
oversold
MACD trend Positive
52-week position 18%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −19%
trailing
6-month return −56%
trailing
YTD return −36%
this year
Relative strength −74%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $15 › 200d $17 — 200d above 50d
Institutional flow Accumulating
+3% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.93% of float · ▲ +22.8% MoM · 4.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
150 holders — near 2-yr high, broad support
Squeeze score 65
elevated · 0–100
Fundamentals
Strong
EPS growth +66%
Y/Y
Free cash flow $-82.3M
Balance sheet $186.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 109%
annualized · 1-yr
Max drawdown −66%
past year
ATR 9.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−50% Bearish
Price vs 50-day avg
−44% Bearish
RSI (14)
29 Neutral
MACD trend
Positive Bullish
52-week position
18% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $15 › 200d $17 — 200d above 50d
Institutional flow Accumulating
+3% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.93% of float · ▲ +22.8% MoM · 4.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
150 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $5 Now $8 · 18% Range high $25
vs 200-day avg -50% vs 50-day avg -44%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BIOA
BioAge Labs, Inc.
this stock
$389.66M -35.8% — — 5.9%
TAK
Takeda Pharmaceutical Co Ltd
 $58.31B +17.1% — — 0.1%
GALDY
Galderma Group AG/ADR
 $44.03B -8.9% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $43.22B +18.8% +4.3% 60.8 3.2%
HLN
Haleon plc
 $40.41B -9.1% — — 0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
150
% held
84.4%
Net QoQ
+4.3M sh
Top holder
a16z Capital Management,…
Held Float
View
Held by Funds
Fund positions
160
View
Short & Settlement
Short Interest Rising
Shares short
2.7M
Days to cover
4.7d
Change
+505.1K sh
View
Short Volume
Short vol %
38%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
12.1K
Value
$262.8K
As of
Jul 27, 2026
View
Off-Exchange
Off-exchange %
45.0%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$9.0M
Net income (FY)
$-80.6M
EPS diluted
$-2.24
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 5, 2026
This year
13
View
Proposed Sales
Value
$509.2K
Shares
20.2K
Filed
Jun 30, 2026
View
Exempt Offerings
Offering
$194.4M
Filed
Feb 13, 2024
View
Earnings & Events
Earnings Calls
Last call
Aug 5, 2026
View

Performance

5D 20D 120D MTD YTD
BIOA -10.6% -18.6% -56.0% -10.6% -35.8%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -9.5% -16.9% -73.9% -10.3% -47.9%
Key facts CIK 1709941 CUSIP 09077V100 13F (30d) 67 filings 67 filers Visit website Investor relations